Oramed Pharmaceuticals (ORMP) Cash & Equivalents (2010 - 2026)

Oramed Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $13.2 million for Q1 2026.

• Quarterly Cash & Equivalents fell 82.28% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (down 82.28% YoY) and the FY2025 annual result came in at $45.9 million, down 15.57% from the prior year.
• Cash & Equivalents was $13.2 million for Q1 2026 at Oramed Pharmaceuticals, down from $45.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $84.8 million in Q2 2024 and bottomed at $435000.0 in Q2 2025.
• A 5-year average of $30.1 million and a median of $28.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 1152.45% — and 2025, when it plunged 99.49%.
• Oramed Pharmaceuticals' Cash & Equivalents stood at $40.5 million in 2022, then sank by 77.62% to $9.1 million in 2023, then soared by 500.99% to $54.4 million in 2024, then slipped by 15.57% to $45.9 million in 2025, then plunged by 71.27% to $13.2 million in 2026.
• Business Quant data shows ORMP's Cash & Equivalents at $13.2 million in Q1 2026, $45.9 million in Q4 2025, and $868000.0 in Q3 2025.